Hologic (NASDAQ:HOLX) Issues FY 2025 Earnings Guidance

Hologic (NASDAQ:HOLX - Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 4.250-4.350 for the period, compared to the consensus estimate of 4.070. The company issued revenue guidance of $4.2 billion-$4.2 billion, compared to the consensus revenue estimate of $4.0 billion. Hologic also updated its FY25 guidance to $4.25-4.35 EPS.

Hologic Stock Performance

Hologic stock traded up $1.39 during mid-day trading on Monday, reaching $83.72. 3,327,689 shares of the stock traded hands, compared to its average volume of 1,582,480. The business's 50-day moving average is $80.99 and its 200-day moving average is $78.02. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The stock has a market capitalization of $19.45 billion, a PE ratio of 28.48, a price-to-earnings-growth ratio of 2.93 and a beta of 0.98. Hologic has a 12-month low of $66.93 and a 12-month high of $84.67.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on HOLX shares. JPMorgan Chase & Co. upped their target price on shares of Hologic from $91.00 to $95.00 and gave the company an "overweight" rating in a research report on Tuesday, July 30th. Evercore ISI boosted their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a research report on Tuesday, October 1st. Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. StockNews.com downgraded shares of Hologic from a "strong-buy" rating to a "buy" rating in a report on Friday, September 27th. Finally, Mizuho raised their price target on Hologic from $85.00 to $90.00 and gave the stock an "outperform" rating in a research note on Friday, October 4th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $87.50.

Insiders Place Their Bets

In other Hologic news, insider Brandon Schnittker sold 476 shares of the business's stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.75% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.